Patents by Inventor Ki-Yuk Chang

Ki-Yuk Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175976
    Abstract: The present invention relates to a neovascular-targeting contrast medium composition and a method for preparing same. The neovascular-targeting contrast medium composition according to the present invention exhibits high binding force to neovascularization-associated ?v?3 integrin, excellent tissue permeability and biostability, enables simple measurement in vitro, in vivo, or ex vivo, and thus is effective in the detection of neovascularization and in diagnosing diseases associated therewith, and therefore may be usefully employed in the relevant industries.
    Type: Application
    Filed: July 24, 2019
    Publication date: June 9, 2022
    Applicant: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Ki-Yuk CHANG, Chan-Woo KIM, Kwan-Soo HONG, Hyun-Seung LEE, Hyun-Min KIM
  • Publication number: 20220133913
    Abstract: Disclosed are an ?v?3 integrin targeting single-domain antibody and various applications thereof. The ?v?3 integrin targeting single-domain antibody exhibits high binding ability to ?v?3 integrin related to angiogenesis, excellent tissue permeability, and biostability compared to conventional antibodies. Further, the single-domain antibody may be combined with fluorescent particles and thus may be easily measured in vitro, in vivo or ex vivo, and may be effective in detecting angiogenesis and diagnosing angiogenesis related diseases, therefore it may be usefully used in related industries.
    Type: Application
    Filed: July 24, 2019
    Publication date: May 5, 2022
    Applicant: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Ki-Yuk CHANG, Kwan-Soo HONG, Chan-Woo KIM, Hyeon-Seung LEE, Hyun-Min KIM
  • Patent number: 9833473
    Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 5, 2017
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Ki-Yuk Chang, Eun-Ho Choo, Hyo-Eun Park, Eun-Hye Park, Dae-Seog Lim, Jun-Ho Lee
  • Publication number: 20160095882
    Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Ki-Yuk Chang, Eun-Ho Choo, Hyo-Eun Park, Eun-Hye Park, Dae-Seog Lim, Jun-Ho Lee